Clinical Trials Logo

Clinical Trial Summary

In this study, case information and specimens of patients with malignant hyperthermia(MH) will be collected from all over China, and gene fragment analysis, sanger sequencing method and/or high-throughput whole-genome sequencing will be performed. The MH bioinformatics database will be established to find the pathogenic gene and mutation site of MH in Chinese. Based on the bioinformatics database, the genetic law of MH family will be studied. According to the results of the study, the guideline for the diagnosis and treatment of MH that is in line with Chinese population biology characteristics will be formulated.


Clinical Trial Description

When MH cases or suspected cases occur in China, anesthesiologists can seek help through malignant hyperthermia emergency rescue WeChat group in which experts from all over the country will give therapy instructions. Afterwards, the responsible anesthesiologist will complete the case report form (CRF) and collect family history of MH. The quality of CRF is reviewed by the investigator and all the queries are solved within 1~2 weeks. Upon obtaining the informed consent, all biological specimens of MH confirmed or suspected patients and their blood relations will be collected in the local hospitals and transported to West China Hospital, Sichuan University in dry ice packaging. All specimens will be checked by the trained investigator, registered and labeled in a standardized manner, and then stored in the biological sample bank of West China Hospital, Sichuan University. Firstly, investigators will use the method of gene fragment analysis to detect the samples at the diagnostic mutation sites included in the current European malignant hyperthermia group. Secondly, investigators will use sanger sequencing method to verify the mutation variants. If the screening results are negative, then high-throughput whole-genome sequencing will be performed. The MH bioinformatics database will be established to find the pathogenic gene and mutation site of MH in Chinese. Based on the bioinformatics database, the genetic law of MH family will be studied. According to the results of the study, the guideline for the diagnosis and treatment of MH that is in line with Chinese population biology characteristics will be formulated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04474860
Study type Observational
Source West China Hospital
Contact Bin Liu, MD
Phone +86 18980601540
Email liubinhx@foxmail.com
Status Recruiting
Phase
Start date January 15, 2019
Completion date January 2024

See also
  Status Clinical Trial Phase
Completed NCT05036148 - Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia
Withdrawn NCT02561598 - A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia
Withdrawn NCT01624558 - Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient N/A
Recruiting NCT05402839 - Screening of Malignant Hyperthermia Susceptible Individuals
Active, not recruiting NCT03964870 - Spanish Registry of RYR1 and CACNA1S Polymorphisms
Recruiting NCT04610619 - Multisystem Features of Malignant Hyperthermia or Rhabdomyolysis Related to RYR1 Variants
Terminated NCT02964481 - Malignant Hyperthermia Registry and Genetic Testing